The latest research shows that CD277 specific antibodies can transform BTN3A1 from immunosuppressive molecules to immunostimulatory molecules, thus dynamically stimulating anti-tumor immunity driven by αβ and γδ T cells to block the progression of established ovarian tumors 53. The gene discussed is BTN3A2; the disease is neoplasm.